We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

12 hedge funds and large institutions have $2.61M invested in Adial Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more capital invested

Capital invested by funds: $1.41M → $2.61M (+$1.2M)

71% more funds holding

Funds holding: 7 → 12 (+5)

0.01% more ownership

Funds ownership: 0.01% → 0.01% (+0.01%)

Holders
12
Holders Change
+5
Holders Change %
+71.43%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.26M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$307K
3
Millennium Management
Millennium Management
New York
+$280K
4
Jane Street
Jane Street
New York
+$146K
5
Brown Advisory
Brown Advisory
Maryland
+$125K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.04M +$1.26M +424 +684%
BlackRock
2
BlackRock
New York
$705K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$267K +$307K +103 +468%
Millennium Management
4
Millennium Management
New York
$201K +$280K +94 New
Jane Street
5
Jane Street
New York
$105K +$146K +49 New
Citadel Advisors
6
Citadel Advisors
Florida
$91K +$125K +42 New
Brown Advisory
7
Brown Advisory
Maryland
$89K +$125K +42 New
Two Sigma Investments
8
Two Sigma Investments
New York
$87K +$65.5K +22 +116%
UBS Group
9
UBS Group
Switzerland
$13K +$5.96K +2 +50%
LTFS
10
Ladenburg Thalmann Financial Services
Florida
$4K +$2.98K +1 +100%
Morgan Stanley
11
Morgan Stanley
New York
$2K – – –
Wells Fargo
12
Wells Fargo
California
$2K +$2.98K +1 New

ADIL Hedge Fund Activity: Q1 2019 in Review

12 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2019, worth a combined $2.61M — up 86% from $1.41M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ADIL positions and 0 closed out — a net gain of 5 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.26M.

  • 12 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2019, up from 7 in Q4 2018.
  • Funds reported $2.61M of Adial Pharmaceuticals stock for Q1 2019, up 86% quarter-over-quarter.
  • 5 funds opened new Adial Pharmaceuticals positions in Q1 2019 and 0 closed out, a net change of +5 holders.
  • The largest Adial Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $1.26M added.

Based on aggregated 13F filings for Q1 2019.